

Study to look at the variability of tests of blood vessel function in several different groups of people

Submission date 14/02/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 07/03/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 04/04/2024	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

There are a lot of studies investigating medication that can potentially affect the characteristics of human blood vessels and how they work. To be able to properly explore these effects, reliable, safe and non-invasive tests are needed. This study aims to develop these tests, measuring how much they vary over time and between different people. In the study, different types of cameras and microscopes will be used to look at blood flow in the skin, oxygen content in the skin, the function of skin cells, function of blood vessels and characteristics of small blood vessels. These tests are further explained in the participant information sheet.

Who can participate?

Healthy adult volunteers aged 18 - 30 years.

What does the study involve?

The study consists of two visits, in which all tests described above are done once per participant. All of the tests are non-painful. Total duration of each visit is approximately 2 hours.

What are the possible benefits and risks of participating?

There are no direct benefits of participation in the study, but the data collected will help to improve research in the field. There are no risks associated with participation.

Where is the study run from?

Centre for Human Drug Research (the Netherlands)

When is the study starting and how long is it expected to run for?

December 2021 to February 2022

Who is funding the study?

Centre for Human Drug Research (the Netherlands)

Who is the main contact?
Dr Matthijs Moerland, mmoerland@chdr.nl

Contact information

Type(s)

Principal Investigator

Contact name

Dr Matthijs Moerland

ORCID ID

<http://orcid.org/0000-0002-8064-8426>

Contact details

Zernikedreef 8
Leiden
Netherlands
2333CL
+31 715246454
mmoerland@chdr.nl

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

CHDR2156

Study information

Scientific Title

Observational study to evaluate inter-and intra-subject variability of microcirculatory and endothelial functional tests and differences in these tests between several subject populations

Study objectives

Functional tests of endothelial function and microcirculation can be used to evaluate clinical effects in clinical trials.

Ethics approval required

Old ethics approval format

Ethics approval(s)

No ethics approval required (non-WMO research)

Study design

Observational single-centre longitudinal cohort study

Primary study design

Observational

Secondary study design

Longitudinal study

Study setting(s)

Other

Study type(s)

Other

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Endothelial function and microcirculatory function

Interventions

Eight healthy volunteers will be assessed in this study on two separate study days. The Screening Visit will be conducted at day 1. Each study day subjects will undergo a battery of endothelial testing, which consists of the following measurements: Flow Mediated Skin Fluorescence (FMSF), laser speckle contrast imaging (LSCI), near infrared spectroscopy (NIRS), side-stream dark field microscopy (SDFM) and passive leg movement (PLM), in no particular order. However, LSCI_LTH measurements will be performed after LSCI_PORH.

Intervention Type

Other

Primary outcome measure

Endothelial function and microcirculation measured with FMSF, LSCI, NIRS, SDFM and PLM on two study days

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

03/12/2021

Completion date

20/02/2022

Eligibility

Key inclusion criteria

1. Male and females, 18 to 30 years of age, inclusive.
2. Subject has voluntarily signed informed consent form.
3. Willingness and ability to comply with all study procedures
4. Body mass index (BMI) between 18 and 30 kg/m²

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

8

Key exclusion criteria

1. Evidence of any active or chronic disease or condition that could interfere with the conduct of the study (following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).
2. Receipt of any study drug within 30 days or 5 times ½ half-life, whichever greater prior to day 1.
3. Participation in an investigational drug or device study (last dosing of previous study was within 90 days prior to first dosing of this study).
4. History of abuse of addictive substances (alcohol, illegal substances) or current use of more than 21 units alcohol per week, drug abuse, or regular use of sedatives, hypnotics, tranquillisers, or any other addictive agent.
5. Alcohol intake 24h prior to the study day.
6. Is demonstrating excess in caffeine consumption (more than eight cups of coffee or equivalent per day).
7. If a woman, pregnant, or breast-feeding, or planning to become pregnant during the study
8. Any daily nicotine use or regular use of nicotine products.
9. Positive nasopharyngeal rapid antigen test for SARS-CoV-2 at admission to the clinical research center
10. Subject has received any vaccination in the last 2 weeks prior to Visit 1

Date of first enrolment

01/01/2022

Date of final enrolment

12/02/2022

Locations**Countries of recruitment**

Netherlands

Study participating centre
Centre for Human Drug Research
Zernikedreef 8
Leiden
Netherlands
2333CL

Sponsor information

Organisation
Centre for Human Drug Research

Sponsor details
Zernikedreef 8
Leiden
Netherlands
2333CL
+31 71 524 6400
info@chdr.nl

Sponsor type
Research organisation

Website
<http://www.chdr.nl/>

ROR
<https://ror.org/044hshx49>

Funder(s)

Funder type
Research organisation

Funder Name
Centre for Human Drug Research

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal, possibly combined with data from other trials running at CHDR.

Intention to publish date

20/02/2023

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from CHDR project leader or principal investigator. (clintrials@chdr.nl)

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 1	08/12/2021	18/02/2022	No	Yes
Protocol file	version 1	08/12/2021	18/02/2022	No	No
Results article		12/05/2023	04/04/2024	Yes	No